We evaluated the intrasession and intersession reliability of acoustic rhinometry in measurin g nasal cross-sectional areas in 10 subj ects. Subjects were measured unde r three conditions: with a Breath e Right nasal strip in place, with a sham strip in place, and with no strip in place. Two sets of three measurements were taken 1 week apar t. The intrasess ion reliability both with and witho ut the Breath e Right strip was vel)' goo d (intraclass correlation coefficient [ICC) [ 2,1J: 0.97 and 0.98, respectively). The intersession reliability with and without the Breath e Right strip was not nearly as goo d (ICC [2,1]: 0.62 and 0.6 7). The Breathe Right strip increased the mean nasal cross -sectional area by 0.10 em' (17.4%). We conclude that acoustic rhinotnetry is a reliable way to measure nasal cross-sectional area durin g a single session of multiple tests, but it is not as reliable across sessions. We also determin ed that the Breathe Right nasal strip significantly increases nasal cross-sectional area.
Man y researchers have attested to the validity with which acoustic rhinometry illustrates areas of potential obstruc tion, congestion, and septal abnor malities."?It has also been show n to be an effective way of measurin g nasal cross -sec tional area . 3 . 8 . 9 Furthermore, Silkoff et al reported that the mea surement of nasal cross -sectional areas by aco ustic rhin ometry is reliable across sess ions.'?However, they did not report which specific intracl ass correlation coefficient (ICC) they used in their study, as we have (2, I) , and no other report of intrasession reliabil ity has been publi shed. Also, there has been no publi shed rep ort attesting to the ability of Breathe Right nasal strips to produce a reliable increase in nasal cross-sectional area.
The purp ose of our study was threefold : ( I) to determine the intra-and inter session reli ability of acoustic rhinornetry , (2) to determine its intra-and inter session reliabil ity in measurin g the nasal cro ss-sectional are a with the Breathe Right nasal strip in place , and (3) to determine if the Breathe Right strip increases nasal cro sssectional area significantly better than sham strips or no strips.
Subjects and methods
We used a I x 3 repea ted-meas ures factorial design for this study. Th e repe ated independe nt variable was treatment; the three variables were no strip (control), a sha m strip, and the Breath e Right strip. Th e dependent variable was the cross -sectional area of eac h nostril.
Ten subje cts (mean age : 24. 1 yea rs; mean height: 5 ft ., 7 in.; mean weight: 152.5Ibs.) participated in this study . All subje cts were graduate stude nts at Indiana State University.
Nasal cro ss-sectional area was measur ed with the Eccovision Acoustic Rhinometr y System (E. Benson Hood Laboratories; Pembroke, Ma ss.). Th e rhinometer was properly calibrated accor ding to the manufacturer' s guidelines. "
The nasal cros s-sectional area of both the left and right Nonsedating .
• In a dose-ranging study, Allegra ®w as nonsedating even at 480 mg/d-more than tw ice the recommended qd dose'"
• The most co mmonly reported ad verse events w ith Allegro 180 mg and placebo in seasona l allergic rhinitis patients 12 and older ore headache (10.6% vs 7.5%), upper respiratory tract infection (3.2% vs 3. 1%), and bo ck pain (2.8% vs 1.4%) *Adm inistered as 240 mg bid for 14 days (n= 14 4) . There is no evid ence that doses highe r than those recommended are more effective .
Please see brief summary of prescribing information o n ad jacent page. 
Adverse experience
Back Pain Sinusitis Dizziness Drowsiness OVERDOSAGE Reports of fexofenadine hydrochloride overdose have been infrequent andcontain limited information. However, dizziness, drowsiness, and dry mouth have been reported. Singledoses of fexofenadine hydrochloride up to 800 mg (sixnormalvolunteers atthis doselevel ), anddoses upto 690 mg twicedaily for 1 month (three normal volunteers atthis dose level) or 240mg once dailyfor 1 yea r (234normal voluntee rs at thisdose level ) were administered without thedevelopment of clinically significant adverse events ascomparedto placebo, In theevent of ove rdose, considerstanda rd measures to remove anyunabsorbed drug. Sym ptomatic andsupportivetreatment is recommended.
Hemodialysis didnoteffectively remove texotenadine hydrochloridefrom blood (1.7% removed) following tertenadin e adm inistration.
No deaths occurredat oral dosesof fexofenadinehydrochlorideup to 5000 mglkgin mice(110 times the max imumrecommended daily oral dose in adults and200timesthe maximum recommended daily oraldose in children based on mg/m l ) and up to 5000 mglkgin rats (230 times the maximum recommendeddailyoral dose in adultsand 400 times the max imumrecommended daily oral dose in children based onmg/m 2 ) . Additionally, noclinical signsof toxicity or gross pathologic?lfindings were observed. In dogs, no evidence of toxicity wasobserved at oral doses up to 2000 mglkg(300times themax imumrecommendeddailyoral dose in adults and 530timesthe maximum recommended daily oral dose in childrenbased on mg/m 2 ) .
Chronic Idiopalhic Urticaria
Adverse events reported by pat ients 12years of ageand older in placebo-controlled chronic idiopathic urticaria studies were similar to those reported in place bo-cont rolled seasonal allergi c rhinitis studies. In placebo-controlled chronic idiopathic urticaria clinica l trials, which incl uded 726patient s 12 years of ageand older recei ving fexofenadine hydrochloride tablets at doses 01 20 to 240 mg twice daily, adverse events weresimilarin fexofenadine hydrochloride and placebo-treatedpatients. Table 3 lists adverse experiences in patients aged 12years andolder which were reported by grea ter than 2% of pat ients treated withtexotenadlnehydrochloride60 mg tabletstwicedai ly in controlled clinicalstudies in the United States and. C a~a d a andthatwere more~o~~o n \ ' I t h f~x of~n~ dine hydrochl oride than placebo. The safetyof fexofenadine h y dr~c h l o n d e In the treat men t of chronicidiopathic urticaria In pediatric patients 6 to 11years of age is based on the safetyprofile of fexofenadinehydrochloridein adul ts and adolescent patients at doses equal to or higherthan the recommendeddose(see Pediatric Use). 
The changesin plasma levels were within the range of plasma levelsachieved in ade quate and well-controlledclinical trials. Themechanism of these interactions has been evaluatedin in vitro, in situ,andin vivoanimal models . These studiesindicate that keto- Teratogenic Effect s: Category C. There wasnoevi denceof teratogenicityin rats or rabbits at oral doses of terfenadineup to 300 mglkg (whichled to texctenadine exposures that wereapproximate ly4 and31times, respectivel y,theexposure from the maximum recommended daily oral dose of fexofenadinein adults). There are no ade quate and well controll ed studiesin pregnant wome n. Fexnt enadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects. Dose-related decreases in pupwei ght gain and survivalwere observed in rats exposed to anoral dose of 150mglkg of terfenad ine(approximately3 times the maximum recommend ed dai ly oral dose of fexotenadlne hydrochl oridein adults based on comparison of Iexotenadine hydrochl oride AUCs).
NUrsing Mothers
There areno adequate andwell-controlled studies in women during lactation. Bec ause many drugs areexcreted in human milk, caution should be exercisedwhen texntenadine hydrochloride is administered to a nursing woman.
The recommended dose in patients 6 to 11 yea rs of ageis based on cross-studycompari son of the pharmac okinetics of ALLEGRAin adults and pediatric patient s and on thesafetyprofileof fexofenadinehydrochloridein bothadult and pediatric patients at doses equal to or higher than the recommended doses. Fexcfenadine hydrochloridehad no effect on thepharmacokinetics of eryth romycin and ketoconazoe. In two separate studies, texotenadine hydrochloride 120 mg twice daily (two limes the recommended twicedaily dose)wasco-administeredwith erythromycin 500 mg every8 hours or ketoconazole 400 mg once daily under steadystate conditionsto normal, healthy volunteers (n=2 4, each study).
No differences in adverse eve nts or orc~n terva l were~bserved when patients were administeredfexctenadine hydrochloridealone or in combination with erythromycin or ketoconazole. The findings of these studiesare summar izedin thefollowing table:
*Ad ministered as 240 mg bid for 14 days ! n= 14 4) . There is no evide nce that doses higher than those recommended are more effective. 
Results
The intra sess ion reliability both with and without the Breathe Right strip was very good (ICC [2,1]: 0.97 and 0.98, respective ly) (table) . Th e intersession reliab ility with and without the Breathe Right strip was not nearly as goo d (ICC [2,1]: 0.62 and 0.6 7, respective ly).
Th e nasal cross-sectional area was signific antly larger with the Breathe Right strip in place than it was under both co ntro l (p<O.OOI) and sham conditio ns (p = 0.001 ) ( figure) . Th e Breathe Right strip increased nasal crosssect ional area by o.10ern?(17.4%). There was no significant difference in measurem ent s of cross-sectional areas betw een the sham and control conditi ons (p = 0.073 ). nostril was measured in eac h patient under three co nditions in the following order: with no strip in plac e (co ntrol), with a sham strip in plac e, and with the Breathe Right strip in place. Th e sham strip was similar to the Breathe Right strip except that it did not cont ain the two springs . Three consecuti ve measurement s were mad e under eac h condition. The same inves tiga tor perform ed all measurements.
Th e Breathe Right and sham strips were fitted acro ss the nose in acco rda nce with the instru ctions in the manu facturer ' s package insert. 12 Th e correc t size of the rh inometer nose tip was determin ed by hold ing the tip to the nostril and mak ing sure that the tip forme d a sea l with the nostril without distortin g the shape of the nasal cavi ty. Th e nose tip was then placed on the wave tube, and a sea l was made with the subje ct's nostril. The subjec t was instructed to sit up straig ht, inhale, and hold his or her breath dur ing the measurem ent of eac h nostril.
Seven da ys after the initial testing, another set of measurement s was made under the same conditions. These new measurements served as the basis for the inter session comparison.
The ICC (2, I) was used to calculate the intra -and intersess ion reliability of the nasal cross-sectional measurem ent s in each of the three co nditions." Changes in nasal cross -sec tional area indu ced by the Breathe Right nasal strip were determin ed acco rding to one -way repeated-measures ANO VA and Bonferroni corrected pairwise co mparisons. A probab ility of p<0.05 was co nsidere d to be statistica lly significant.
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Discussion
The res ults of this study demonstrate that the intrasession reliabi lity of aco ustic rhin ometry to measure nasal cros ssec tional area was much better than its intersession reliability. Roithmann et al reported similar findings rega rding the reproducibility of aco ustic rhin ometry measurements over time." They obse rved that when subjects were retested at weekly intervals, there was a variability of 17% in the total minimum cro ss-sectional area . Silkoff et al record ed ave rage variab ility coeffic ients of 8. I and 9.7% for right and left nostril s ove r five sess ions.v' They did not report intra session reliability because their methodology required that they keep measuring the cross-sectional area until they reco rded four measurement s that varied by less than 10%.
Roithmann et al found a variability of 5% durin g minut e-to-minute measurement s, much less than the 17% variability for week-to-week measurem ents.1-1 In another study, Roithmann et al reported a one-session variability coefficient of less than 10%. 15 In our study, we found that the Breath e Right nasal strip increased nasal cross-sectional area by 17.4%. A similar 
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Th e autho rs thank eNS , Inc., for its donation of the Brea the R ight and sham str ips that were used in this study. increase (2 1%) was reported by Port uga l et al.' Th ey found that the increase was co nsistently seen at the level of the nasa l valve, whic h is the area of greatest nasal resi stan ce . Th e re fo re, w he n Breat he Right strips are correctly applied, they sho uld decrease the amount of nasa l airway res ista nce. Ng et al also fou nd that the Breathe Right strips significantly increased nasal cross-sectional area." Gosepath et al noted increases of 9 and 37 % in nasa l cross -sec tio nal area at two different planes. " They spec ulated that the "s trips may enhance nasal ventilatio n by mec hanical cha nges in nasa l geometry." Th is clai m needs to be studied fur ther.
Th e intersess ion relia bility of acoustic rhino me try in our study was not as grea t as its intrasess ion reliability. At this time, there is no sta nda rdized method for measuring nasal cross-sectio nal area, so differences between meas urements are likely. '? These differences ca n occur beca use of nasal mucosal var iatio ns over time,14 the subject's posture,14 or a poor positioning of the aco ust ic rhinometer so that it distorts the dimensions of the nasa l cav ity or fails to for m a goo d sea l with the nostril. 14. 17 We made every effort to control this variable among subjects and between trials , but some variability did occ ur, as was reflected in our reliability coefficie nts. To decrease the effects of the nasal cycle , our subjects were meas ured at approximately the same time of day at both testing sess ions. Also, we used an average of three measurements so that errors could be minimized. Tomkinson and Eccles have recommended a stan dardized procedure that might reduce the varia bility of measurements as well as esta blis h a norm for rhinometer operators to follow . 17 We conclude that acoustic rhino metry is a reli able way of measuri ng nasal cross-sectiona l area during a sing le testing session . We also co nclude that nasa l cross-sectiona l area measurements by aco ustic rhinometry with the Breathe Right strip in place are very reliable. The intersession reliabili ty of rhinometry both with and without the Breathe Right strip in place was cons iderably less. As ind ividu al ope rators become more experienced in using rhinometers, their relia bility ove r time shou ld improve.
Our study also demonstrates that the Breat he Right nasal strip reliably and sign ificantly increases nasal crosssec tional area .
